Pyxis Oncology

PYXS
1.8107.74% ( +0.130 )
Closed: Nov 20, 16:00:00 (EDT)

Valuation

Current ValuationThe current P/E ratio is -2.32, within the reasonable range, cheaper than 61.73% of the time in the past 3 years, and the industry ranks 317/607, the industry Median -1.63.

-2.32xP/E
Stock price$1.68Earnings per share$-0.72

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
013263952

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GILDUSGilead Sciences
-53.48x162.72%$206.55B
MRNAUSModerna
-28.53x0.44%$79.58B
CSLLYUSCSL Limited
-24.52x--$63.24B
NTRAUSNatera
-255.23x4.11%$42.04B
RVMDUSRevolution Medicines
-18.27x40.11%$34.17B
INSMUSInsmed
-52.33x74.85%$31.69B
ROIVUSRoivant Sciences
-81.98x102.68%$28.23B
BNTXUSBioNTech SE
-11.92x26.17%$20.18B
BBIOUSBridgebio Pharma
-25.72x31.00%$15.23B
BMRNUSBioMarin Pharma
-622.38x55.46%$11.90B
KYMRUSKymera Therapeutics
-28.41x8.74%$9.93B
SYREUSSpyre Therapeutics
-41.39x59.92%$9.27B
PCVXUSVaxcyte
-8.04x42.32%$9.24B
MDGLUSMadrigal Pharma
-59.28x86.62%$9.22B
PRAXUSPraxis Precision Medicines
-24.18x0.35%$8.69B
SMMTUSSummit Therapeutics
-10.13x24.19%$8.43B
RYTMUSRhythm Pharma
-40.84x51.65%$8.10B
ALKSUSAlkermes
-22,108.98x133.70%$7.76B
TWSTUSTwist Bioscience
-56.44x34.79%$7.35B
CGONUSCG oncology
-30.81x41.23%$7.32B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.